Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Mohamed K. Mohamed"'
Publikováno v:
Tikrit Journal of Engineering Sciences, Vol 27, Iss 2 (2020)
The computer control plays important role in the solar cell design and development of dual axis solar tracker for the sun's position. The main goal of this paper is to maximize energy output to reduce panel temperature (cooling), to increase efficien
Externí odkaz:
https://doaj.org/article/8444c2bd353b4194a345850776f3ff79
Publikováno v:
Journal of Medicine in Scientific Research, Vol 1, Iss 4, Pp 219-226 (2018)
Aim The aim of this study was to investigate the effects of renal transplantation on cardiac function and morphology in patients with ESRD on regular hemodialysis at the post-transplant period. Background End stage renal disease (ESRD) is considered
Externí odkaz:
https://doaj.org/article/6e84852d24254ae6b752c1f25ace0298
Autor:
Ahmed, A Emara, Basel, A Sleem, Abdelrahman, K Nageeb, Nouran, H Ahmed, Nada, T Mohamed, Mai, I Hassanin, Reem, M Mohamed, Manar, E Hassan, Mayada, R Shamroukh, Mohamed, K Mohamed, Manal, M Hassaan, Rasha, M Maddy, Mona, S Elneklawi, Mohamed S, Bondok, Ali A, Ali, Mohammed, A Hussein
Publikováno v:
Pakistan journal of biological sciences : PJBS. 25(4)
lt;bgt;Background and Objective:lt;/bgt; Cadmium is a heavy metal that has a wide range of applications in human existence. Cadmium may bind to the protein metallothionein and decrease kidney function once it enters the body. The purpose of this stud
Publikováno v:
Tikrit Journal of Engineering Sciences. 27:71-81
The computer control plays important role in the solar cell design and development of dual axis solar tracker for the sun's position. The main goal of this paper is to maximize energy output to reduce panel temperature (cooling), to increase efficien
Autor:
Ben C. Creelan, Ang Li, Mohamed K. Mohamed, Nivedita Aanur, Shruti Agrawal, Jason C. Chandler, Kenneth B. Blankstein, Michael McCleod, Craig H. Reynolds, Abderrahim Oukessou, Leora Horn, Petros Nikolinakos, David R. Spigel, Tarek Mekhail, David M. Waterhouse
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:679-686
Nivolumab has been administered using a 60-min infusion time. Reducing this time to 30 min would benefit both patients and infusion facilities. This analysis compared the safety of 30- and 60-min infusions of nivolumab in patients with previously tre
Publikováno v:
Journal of Clinical Oncology. 39:96-96
96 Background: Improving healthcare value requires new models of care including higher utilization of outpatient services. A significant social determinant of health in this mode of care is transportation, and the most vulnerable segments of society
Autor:
Joel N. Saltzman, Alan P. Lyss, Chandra P. Belani, Mohammed A. Kassem, Jerome D. Winegarden, Joan H. Schiller, Thomas E. Stinchcombe, Suzanne E. Dahlberg, Gopakumar S. Nambudiri, Nathan A. Pennell, John McCann, Leora Horn, Mohamed K. Mohamed, Jan M. Rothman, Suresh S. Ramalingam
PURPOSE Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non–small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400ca8732da050ca587406a048512f38
https://europepmc.org/articles/PMC7001786/
https://europepmc.org/articles/PMC7001786/
Publikováno v:
Journal of Clinical Oncology. 38:e21734-e21734
e21734 Background: Lung cancer is the leading cause of cancer death in the US. Significant improvements in survival have occurred with improved treatments. Payer status has been recognized as a barrier to treatment access across multiple cancer types
Autor:
Suzanne McMullen, Kerstin Müller, Edward S. Kim, Sarah Goring, Jennifer L. Ersek, Antoinette J. Wozniak, David M. Waterhouse, Himani Aggarwal, Benjamin Levy, Catherine Muehlenbein, Katherine B. Winfree, Ana B Oton, Mohamed K. Mohamed, Lisa M. Hess, Yajun Zhu
Publikováno v:
The Patient
Introduction Advanced non-small cell lung cancer (NSCLC) is a severe disease with burdensome symptoms and traditionally poor outcomes. The treatment of advance disease is based on chemotherapy, with the recent addition of immunotherapy. Patients who
Autor:
Karen Kelly, Jeffrey Warren Allen, Mohammad Jahanzeb, Shirish M. Gadgeel, David R. Gandara, Hanna M. Saba, James C. Moon, Mohamed K. Mohamed, Mary W. Redman, Philip C. Mack
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 32, iss 23
Allen, JW; Moon, J; Redman, M; Gadgeel, SM; Kelly, K; Mack, PC; et al.(2014). Southwest Oncology Group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. Journal of Clinical Oncology, 32(23), 2463-2470. doi: 10.1200/JCO.2013.51.4109. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/69z0p887
Allen, JW; Moon, J; Redman, M; Gadgeel, SM; Kelly, K; Mack, PC; et al.(2014). Southwest Oncology Group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. Journal of Clinical Oncology, 32(23), 2463-2470. doi: 10.1200/JCO.2013.51.4109. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/69z0p887
Purpose Development of new therapies for previously treated small-cell lung cancer (SCLC) is a major unmet need. Here, we describe a randomized, phase II trial of weekly topotecan with or without ziv-aflibercept (VEGF-trap) in this clinical setting.